PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
9 hedge funds and large institutions have $99.1K invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.98% less ownership
Funds ownership: 1.2% → 0.22% (-0.98%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
74% less capital invested
Capital invested by funds: $374K → $99.1K (-$275K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$21.1K |
| 2 |
SG
StoneX Group
New York
|
+$15.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$216K |
| 2 |
VF
Virtu Financial
New York
|
-$20K |
| 3 |
Millennium Management
New York
|
-$16.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$539 |
PHXM Hedge Fund Activity: Q2 2023 in Review
9 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q2 2023, worth a combined $99.1K — down 74% from $374K a quarter earlier.
Fund positioning in PHXM was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Baader Bank Aktiengesellschaft, opening a new position worth an estimated $21.1K. The largest seller was Ikarian Capital, cutting an estimated $216K.
- 9 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $99.1K of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q2 2023, down 74% quarter-over-quarter.
- 2 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q2 2023 was Baader Bank Aktiengesellschaft, an estimated $21.1K added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q2 2023 was Ikarian Capital, an estimated $216K sold.
Based on aggregated 13F filings for Q2 2023.